Last mentioned: Mar 25, 2026
Phase III Milestones
Anticipated data readouts for TCT imaging agents supported by Cu-64 supply.
Supply Chain Integration
Integration of Theragenics' output into Clarity's clinical trial logistics.
Production Ramp-up
Expected commencement of large-scale isotope production for late-stage clinical trials.
Process Integration
Technical teams begin integrating manufacturing protocols and quality control standards.
Agreement Signed
Clarity and Theragenics formalize the large-scale manufacturing supply deal for Cu-64.
Supply Agreement Signed
Clarity and Theragenics formalize large-scale Cu-64 manufacturing partnership.
Reporting Season Pressure
Difficult February reports for CSL and Sonic Healthcare extend index declines.
Anteris Funding
Anteris Technologies raises approximately $440 million for heart valve technology.
Nasdaq Biotech Peak
The index records a 30% annual gain, diverging from broader tech markets.
Record Funding Year
Clarity ($200m) and Mesoblast ($260m) complete significant capital raises.
ASX Healthcare Slump
The sector begins a calendar year decline of 25% led by major heavyweights.
Clarity Pharmaceuticals has signed a major manufacturing supply agreement with Theragenics to secure large-scale production of copper-64. This partnership bolsters the supply chain for Clarity’s Targeted Copper Theranostics platform as it moves toward late-stage clinical trials.
Clarity Pharmaceuticals has entered into a multi-year manufacturing supply agreement with Theragenics for the production of copper-64 (Cu-64). This partnership secures a reliable, large-scale supply of the isotope to support Clarity's clinical trials and future commercialization of its Targeted Copper Theranostics platform.
Clarity Pharmaceuticals has secured a large-scale manufacturing supply agreement with Theragenics for the production of copper-64. This strategic partnership addresses critical supply chain bottlenecks for radiopharmaceuticals, ensuring a reliable flow of isotopes for Clarity’s diagnostic and therapeutic clinical trials.
The global healthcare sector is splitting into a 'two-speed' market as regulatory uncertainty under the Trump administration pressures established giants while innovative biotechs find significant capital. Despite a 25% decline in the ASX 200 healthcare index, smaller players are leveraging AI and record-setting capital raises to navigate a complex FDA landscape.
The global biotech sector has diverged into a 'two-speed' market, where innovative drug discovery and device firms are outperforming established healthcare heavyweights. Despite regulatory uncertainty under the Trump administration and a 25% decline in the ASX 200 healthcare sector, the Nasdaq Biotech Index has surged 30%, supported by record-breaking capital raises.
The global healthcare sector is bifurcating as mid-cap biotech innovators outperform established heavyweights despite regulatory headwinds from the Trump administration. While the ASX 200 healthcare index fell 25% in 2025, a surge in capital raising and AI integration is fueling a resilient 'engine room' of drug discovery and device innovation.